Otelixizumab: Additional Phase II data

Additional data from a double-blind, placebo-controlled, European Phase II trial in 64 evaluable patients with Type I diabetes showed that otelixizumab given for 6 days preserved beta cell function and delayed the rise in insulin requirements for up to 48 months. Data were published in Diabetologia. Previous data showed that otelixizumab preserved beta cell function and reduced insulin needs for at least 18 months (see BioCentury, June 27, 2005). ...